1. OC03.05: Intravenous immunoglobulin for the treatment of severe maternal alloimmunisation: individual patient data meta‐analysis.
- Author
-
Mustafa, H., Sambatur, E., Pagani, G., D'Antonio, F., Maisonneuve, E., Maurice, P., Zwiers, C., Verweij, J., Flood, A., Shamshirsaz, A., Jouannic, J., and Khalil, A.
- Subjects
ERYTHROBLASTOSIS fetalis ,ERYTHROCYTES ,NEONATAL death ,HOSPITAL admission & discharge ,INTRAVENOUS immunoglobulins ,HYDROPS fetalis - Abstract
This article, titled "OC03.05: Intravenous immunoglobulin for the treatment of severe maternal alloimmunisation: individual patient data meta-analysis," explores the outcomes associated with the use of maternal intravenous immunoglobulin (IVIG) in high-risk pregnancies with red blood cell (RBC) alloimmunisation. The researchers conducted a systematic search of various databases and included studies that reported on pregnancies with severe RBC alloimmunisation and were treated with IVIG. The analysis of individual patient data from eight studies showed that IVIG was associated with prolonged gestational age at first intrauterine transfusion, reduced risk of fetal hydrops and fetal demise, and increased chances of livebirth and survival. The study suggests that IVIG treatment may have a beneficial effect on the course and severity of severe early hemolytic disease of the fetus and newborn (HDFN) in at-risk pregnancies. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF